Inquiry Basket
    1. Home
    2. New Products
    3. Native Antigens for Vaccine R&D

    Native Antigens for Vaccine R&D

    Our range of vaccine R&D reagents include more than 40 native antigens of key infectious pathogens, including Corynebacterium diphtheriae, Clostridium tetani, Enterovirus, Hepatitis virus, Influenza virus, Poliovirus, Rotavirus, Streptococcus pneumoniae, and Zika virus. These antigens can be used in a variety of applications, from the development of conjugate vaccines, to the evaluation of vaccination efficacy by antibody tests.

    Conjugate vaccines

    Diphtheria and tetanus are two infectious diseases that are particularly dangerous to babies. Chemically detoxified bacterial toxins (toxoids) have been successfully used as vaccines for the prevention of diphtheria and tetanus, DT (diphtheria and tetanus) vaccine, Td (tetanus and diphtheria) vaccine and many other combination vaccines. Tetanus toxoid (TT), diphtheria toxoid (DT) and diphtheria CRM197 are also widely used as protein carriers in licensed vaccines (Hib, pneumococcal, and meningococcal) to develop strong immune responses. Conjugate vaccines rely on these immunogenic molecules to stimulate long-lasting immunity to attached polysaccharides or peptides.

    Native Antigens for Vaccine R&DFig. 1 Preparation processes of licensed Hib conjugate vaccines (Costantino P, et al. 2011)

    Pneumococcal vaccines

    The capsular polysaccharide (CPS) is the dominant surface structure of Streptococcus pneumoniae (S. pneumoniae) and plays a critical role in defense against the host immune system. There are two polyvalent pneumococcal vaccines with CPS-based formulations approved for use in the United States: Prevnar13 (PCV13) and Pneumovax 23 (PPSV23). Prevnar13 is for adults 18 years of age and older by 13 S. pneumoniae serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A,19F, and 23F), all of them are individually conjugated to a CRM197 protein. Pneumovax 23 is for adults 50 years of age or older and persons aged ≥2 years by 23 S. pneumoniae serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). The detection of serotype-specific antibody levels in human sera is very important for differential diagnostics of pneumococcal infections and assessment of immunologic responses after pneumococcal vaccination.

    Native Antigens for Vaccine R&DFig. 2 Pneumococcal conjugation (Deng JZ, et al. 2022)

    Cat_NProduct Name
    DAGC723S. pneumoniae Type 1 CPS-CRM197 conjugate
    DAGC724S. pneumoniae Type 3 CPS-CRM197 conjugate
    DAGC725S. pneumoniae Type 4 CPS-CRM197 conjugate
    DAGC726S. pneumoniae Type 5 CPS-CRM197 conjugate
    DAGC727S. pneumoniae Type 6A CPS-CRM197 conjugate
    DAGC728S. pneumoniae Type 6B CPS-CRM197 conjugate
    DAGC729S. pneumoniae Type 7F CPS-CRM197 conjugate
    DAGC730S. pneumoniae Type 9V CPS-CRM197 conjugate
    DAGC731S. pneumoniae Type 14 CPS-CRM197 conjugate
    DAGC732S. pneumoniae Type 18C CPS-CRM197 conjugate
    DAGC733S. pneumoniae Type 19A CPS-CRM197 conjugate
    DAGC734S. pneumoniae Type 19F CPS-CRM197 conjugate
    DAGC735S. pneumoniae Type 23F CPS-CRM197 conjugate
    Cat_NProduct Name
    DAGC700S. Pneumoniae Type 1 CPS
    DAGC701S. pneumoniae Type 2 CPS
    DAGC702S. pneumoniae Type 3 CPS
    DAGC703S. pneumoniae Type 4 CPS
    DAGC704S. pneumoniae Type 5 CPS
    DAGC705S. pneumoniae Type 6B CPS
    DAGC706S. pneumoniae Type 7F CPS
    DAGC707S. pneumoniae Type 8 CPS
    DAGC708S. pneumoniae Type 9N CPS
    DAGC709S. pneumoniae Type 9V CPS
    DAGC710S. pneumoniae Type 10A CPS
    DAGC711S. pneumoniae Type 11A CPS
    DAGC712S. pneumoniae Type 12F CPS
    DAGC713S. pneumoniae Type 14 CPS
    DAGC714S. pneumoniae Type 15B CPS
    DAGC715S. pneumoniae Type 17F CPS
    DAGC716S. pneumoniae Type 18C CPS
    DAGC717S. pneumoniae Type 19A CPS
    DAGC718S. pneumoniae Type 19F CPS
    DAGC719S. pneumoniae Type 20 CPS
    DAGC720S. pneumoniae Type 22F CPS
    DAGC721S. pneumoniae Type 23F CPS
    DAGC722S. pneumoniae Type 33F CPS

    Viral vaccines

    There are few specific therapies for viral infections, vaccination is an effective way to prevent viral infections. Viral vaccines contain either inactivated viruses or attenuated (alive but not capable of causing disease) viruses. These viruses lost their ability to replicate and are not pathogenic but they can induce an immune response. To cause immune reaction, it contains more antigen than live vaccines. There are several licensed viral vaccines use in the US: Hepatitis A vaccine, Influenza virus vaccine, Poliovirus vaccine, and Rotavirus Vaccine. Currently, there are still many viral vaccines under pre-clinical and clinical stages.

    References

    1. Costantino P, Rappuoli R, Berti F. (2011). The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opinion Drug Discovery. 6(10), 1045-1066.
    2. Paton JC, Trappetti C. (2019). Streptococcus pneumoniae Capsular Polysaccharide. Microbiology Spectrum Journal Homepage. 7(2).
    3. Deng JZ, Lancaster C, Winters MA, et al. (2022). Multi-attribute characterization of pneumococcal conjugate vaccine by Size-exclusion chromatography coupled with UV-MALS-RI detections. Vaccine. 40(10), 1464-1471.
    Cat_NProduct Name
    DAG2692Tetanus Toxoid (TT)Inquiry    
    DAG2689Diphtheria Toxoid (DT)Inquiry    
    DADF-086Diphtheria CRM197Inquiry    
    DAGL0481Polyribosyl Ribitol Phosphate (PRP)Inquiry    
    Cat_NProduct Name
    DAGC694Inactivated Coxsackievirus A16Inquiry    
    DAG-EV71Inactivated Enterovirus 71 VirusInquiry    
    DAG178Inactivated Hepatitis A VirusInquiry    
    DAG-WT664Inactivated IAV H1N1Inquiry    
    DAG-WT665Inactivated IAV H3N2Inquiry    
    DAG-WT666Inactivated IAV H5N1Inquiry    
    DAG-WT667Inactivated IAV H7N9Inquiry    
    DAG-WT668Inactivated IBVInquiry    
    DAGC457Inactivated RotavirusInquiry    
    DAGC691Inactivated Sabin Poliovirus Type IInquiry    
    DAGC692Inactivated Sabin Poliovirus Type IIInquiry    
    DAGC693Inactivated Sabin Poliovirus Type IIIInquiry    
    DAGC460Inactivated Zika VirusInquiry